Navigation Links
Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva
Date:12/21/2009

CARLSBAD, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer. Teva and OncoGenex will collaborate on a global Phase 3 clinical program for OGX-011 in patients with prostate and non-small cell lung cancer.

"We are pleased with OncoGenex' selection of Teva Pharmaceuticals, a leading pharmaceutical company, as a partner to complete the development and commercialization of OGX-011. OGX-011 will be the second antisense drug to enter Phase 3 development from our second-generation antisense technology. We are encouraged by the Phase 2 results of OGX-011 presented earlier this year in patients with advanced prostate cancer and look forward to the drug progressing into a broad Phase 3 program," said B. Lynne Parshall, COO and CFO of Isis Pharmaceuticals. "2009 has been an eventful year for Isis' satellite companies, continuing to affirm our strategy of maximizing the value of our antisense drug discovery platform with both traditional and unique partnerships. Not only do these relationships provide continuing short-term benefit, but, as drugs move forward in the hands of capable partners, they promise significant benefit to patients and more significant financial rewards to Isis in the future."

Under the terms of OncoGenex' agreements with Teva, Isis will receive $10 million
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ISTA Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Once-Daily XiDay(TM)
2. Vion Pharmaceuticals Files for Chapter 11 Bankruptcy
3. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
4. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
5. Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital
6. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
7. Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
8. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
9. Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program
10. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
11. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Calif. , March 31, 2015  Frequentz Inc., ... has released a white paper to help the pharmaceutical ... 2013 Drug Supply Chain Security Act (DSCSA). The white ... stages of the GS1 EPCIS Standard(s) and ... outlook on the product tracing requirements that need to ...
(Date:3/31/2015)... 31, 2015 Medela has announced the ... Invia ® Motion™-Endure personal pumps to its Negative ... services. These new devices, along with the Invia ... to provide innovative, high-quality NPWT solutions, designed to ... patients. "We are happy to be ...
(Date:3/31/2015)... 31, 2015 PGI has announced an expansion ... North America at its San ... anticipated plant expansion is centered on solving the challenge ... products for personal care product manufacturers. ... in-line slitting and packaging, will allow customers to take ...
Breaking Medicine Technology:Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 2Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 3Medela Launches Product Line to Support Individualized Care For Negative Pressure Wound Therapy Patients 2PGI Expands Manufacturing Capabilities At Mexico Plant 2
... 2010 The rheumatoid arthritis treatment,Humira will replace Lipitor as the ... the biggest seller of medicines after,the patent cliff according to the World ... biotech analysis. , , , ... The cancer treatment Avastin had been widely expected to emerge ...
... , WILMINGTON, Del. , April 30 ... Food and Drug Administration (FDA) has approved VIMOVO™ ... relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ... developing gastric ulcers in patients at risk of developing ...
Cached Medicine Technology:Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot 2Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot 3Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot 4Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot 5FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 2FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 3FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 4FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 5FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 6FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 7FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 8FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 9
(Date:4/1/2015)... Natural fertility experts from around the world will ... Integrative Fertility Symposium ( https://ifsymposium.com/ ) April 30th to ... 515 West Hastings Street, Vancouver BC. There will also ... pm to 5:00 pm at Harbour Centre. , "The ... in the world to bring together reproductive endocrinologists, urologists, ...
(Date:4/1/2015)... Raleigh, NC (PRWEB) April 01, 2015 ... treatment option available to them, thanks to the FDA’s ... here to read the full story on the ... vaccine made from a modified version of the bacteria ... agreed to give its manufacturer grant funding and other ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 Eighty ... in athletics grants from California Casualty . Many ... or reduced-cost lunches and subsequently have fewer and fewer ... named after California Casualty Chairman Emeritus Thomas R. Brown, ... translated to the classroom. Since its inception in ...
(Date:4/1/2015)... North Carolina (PRWEB) April 01, 2015 ... and assisted living placement counseling, recently opened a new office ... Amada franchise partners Tracy and Lee Bissett decided to make ... rights to the area after over 20 years of experience ... on Thursday, April 2nd. , When asked what ...
(Date:4/1/2015)... On April 1st, 2015, Dr. Jason Helfrich, co-founder of 100% ... discuss the epidemic known as “Text Neck.” The average human head ... which it is bent forward, such as when bent to look ... cause poor posture often times leading to wear and tear of ... on their cell phone device emailing, keeping up with social media ...
Breaking Medicine News(10 mins):Health News:Vancouver Hosts the World's First Integrative Fertility Symposium 2Health News:Vancouver Hosts the World's First Integrative Fertility Symposium 3Health News:Orphan Drug Approval May Mean New Treatment Option for Mesothelioma, According to Surviving Mesothelioma 2Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 2Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 3Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 4Health News:California Casualty Teams Up With 87 High Schools, Awarding Over $100,000 in 2015 Thomas R. Brown Athletics Grants 5Health News:Amada Senior Care Expands to Eastern North Carolina 2Health News:Dr. Jason Helfrich, Co-Founder of 100% Chiropractic, is a Guest on Better TV to Discuss “Text Neck” 2
... one day lead to new targets, treatments, researcher says , ... have spotted two new regions of the human genome that ... The findings, published in the June issue of the ... patients or people at risk for the devastating dementia just ...
... 2010 Researchers at the Translational Genomics Research Institute ... Virginia G. Piper Cancer Center at Scottsdale Healthcare have ... of patients with an aggressive type of lung cancer. ... which patients with small cell lung cancer are resistant ...
... CA (June 14, 2010) Apple juice can be a useful ... the normal progression of moderate-to-severe Alzheimer,s Disease (AD), according to ... Other Dementias (AJADD), published by SAGE. In the ... of apple juice a day for a month, their caregivers ...
... HOUSTON - Margaret M. Fields, an advanced practice nurse ... Department of Gynecologic Oncology, is the recipient of the ... by The Brown Foundation, Inc. A committee of ... staff reviewed nominations from peers and patients before selecting ...
... ... on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen’s Prolia is the newest ... every 6 months via injection. , ... (Vocus) June 14, 2010 -- According to a recent analysis by SDI , ...
... describes the current state of the science in combating ... In his article in the June 10, 2010 ... Neuroblastoma," Maris reviews the field,s latest research knowledgemuch of ... at The Children,s Hospital of Philadelphia. Maris directs a ...
Cached Medicine News:Health News:Scientists Spot More Genes Related to Alzheimer's 2Health News:TGen-VARI-SHC research helps predict success with cancer drugs 2Health News:TGen-VARI-SHC research helps predict success with cancer drugs 3Health News:Peg Fields to receive MD Anderson's highest nurse-oncologist honor 2Health News:Peg Fields to receive MD Anderson's highest nurse-oncologist honor 3Health News:SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option 2Health News:Internationally known neuroblastoma expert reviews progress versus challenging childhood cancer 2
... trocar has a sharp linear blade and a ... VERSAPORT™ PLUS V2 trocar is available in 5 ... 5 mm-12 mm long sizes with a radiolucent ... has a sharp linear blade and a spring-loaded ...
The Auto Suture™ Woodford Spike™ Trocar and Cannula is a sterile, single-use device designed for primary punctures during laparoscopy. Dexide refers to a separate offering of trocars from...
... of Surgical Access ...unlike any trocar system ... system is actually four systems in one ... and clinically adaptive to all of your ... and bladed or dilating tip styles, OnePort™ ...
Mini-Finesse 5mm Dilating Trocar, hook electrode, two lengths, mini or basic kit....
Medicine Products: